Sign In
Buy IMVT
$31.15
+0.230 (+0.744%)
At Close: Jun 03, 2026
Immunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potential
06:27am, Monday, 25'th May 2026
Immunovant's underlying bull case has now moved away from batoclimab and toward IMVT-1402. This newer asset has encouraging data for difficult-to-treat RA. By week 16, 72.7% of hard-to-treat RA patien
Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy
01:09pm, Thursday, 21'st May 2026
Roivant (ROIV) remains a Buy as its unique 'vant' structure rapidly advances and monetizes blockbuster assets, notably through Immunovant's IMVT-1402 in rheumatoid arthritis. IMVT-1402 delivered stron
These Analysts Increase Their Forecasts On Immunovant After Q4 Results
12:07pm, Thursday, 21'st May 2026
Immunovant Inc (NASDAQ:IMVT) on Wednesday posted a wider fourth‑quarter loss than analysts expected.
IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data
10:20am, Thursday, 21'st May 2026
Immunovant stock jumps 35% as strong early IMVT-1402 data in rheumatoid arthritis boosts confidence despite a wider Q4 loss.
Immunovant Stock Surges Despite Disappointing Earnings Miss
01:09pm, Wednesday, 20'th May 2026
Immunovant Inc (NASDAQ:IMVT) shares are trading higher on Wednesday even though the company posted a wider fourth‑quarter loss than analysts expected.
Immunovant Q4 Earnings Call Highlights
10:08am, Wednesday, 20'th May 2026
Roivant executives used the company's fourth-quarter and fiscal-year earnings call to highlight new clinical data from its development portfolio, upcoming readouts and its strengthened balance sheet f
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026
07:00am, Wednesday, 20'th May 2026
DURHAM, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today report
DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026,
Immunovant (NASDAQ:IMVT) CTO Sells $81,573.48 in Stock
05:02am, Monday, 27'th Apr 2026
Immunovant, Inc. (NASDAQ: IMVT - Get Free Report) CTO Jay Stout sold 2,754 shares of Immunovant stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $29.62, for
Financial Analysis: Arcus Biosciences (NYSE:RCUS) vs. Immunovant (NASDAQ:IMVT)
04:14am, Saturday, 11'th Apr 2026
Arcus Biosciences (NYSE: RCUS - Get Free Report) and Immunovant (NASDAQ: IMVT - Get Free Report) are both mid-cap medical companies, but which is the superior investment? We will compare the two compa
IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints
02:10pm, Monday, 06'th Apr 2026
Immunovant slips 2.4% after batoclimab misses key phase III endpoints in thyroid eye disease trials, despite stable safety and signs of biological activity.
Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP
01:05am, Saturday, 04'th Apr 2026
Roivant Sciences and Priovant Therapeutics executives outlined an expansion of the brepocitinib development program into lichen planopilaris (LPP) and discussed newly released Phase 3 results for bato
Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript
04:32pm, Thursday, 02'nd Apr 2026
Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript
Immunovant's treatment for eye disease fails late-stage trial
05:06am, Thursday, 02'nd Apr 2026
Immunovant said on Thursday that its therapy to treat a type of eye disease failed to meet the main goals in a late-stage study.
Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA
